{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:06Z","timestamp":1790419506482,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.4158\/ep161638.or","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T16:01:50Z","timestamp":1520006510000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY"],"prefix":"10.1016","volume":"24","author":[{"given":"Chiara","family":"Crotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Fabbriciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cavaciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Marasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Massarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP161638.OR_bb0010","first-page":"403","article-title":"A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland","volume":"9","author":"Lippuner","year":"2011"},{"key":"10.4158\/EP161638.OR_bb0015","first-page":"326","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987"},{"key":"10.4158\/EP161638.OR_bb0020","first-page":"956","article-title":"Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995"},{"key":"10.4158\/EP161638.OR_bb0025","first-page":"649","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003"},{"key":"10.4158\/EP161638.OR_bb0030","first-page":"386","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thi\u00e9baud","year":"1997"},{"key":"10.4158\/EP161638.OR_bb0035","first-page":"755","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis","volume":"30","author":"Strampel","year":"2007"},{"key":"10.4158\/EP161638.OR_bb0040","first-page":"464","article-title":"Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial","volume":"28","author":"Welton","year":"2013"},{"key":"10.4158\/EP161638.OR_bb0045","first-page":"4380","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010"},{"key":"10.4158\/EP161638.OR_bb0050","first-page":"447","article-title":"Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion","volume":"25","author":"Bertoldo","year":"2010"},{"key":"10.4158\/EP161638.OR_bb0055","first-page":"101","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005"},{"key":"10.4158\/EP161638.OR_bb0060","first-page":"402","article-title":"No effect of rosuvastatin in the zoledronate-induced acute-phase response","volume":"88","author":"Makras","year":"2011"},{"key":"10.4158\/EP161638.OR_bb0065","first-page":"2337","article-title":"Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid","volume":"22","author":"Silverman","year":"2011"},{"key":"10.4158\/EP161638.OR_bb0070","first-page":"140","article-title":"Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women","volume":"49","author":"Thompson","year":"2011"},{"key":"10.4158\/EP161638.OR_bb0075","first-page":"266","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007"},{"key":"10.4158\/EP161638.OR_bb0080","first-page":"2359","article-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014"},{"key":"10.4158\/EP161638.OR_bb0085","first-page":"390","article-title":"Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease","volume":"7","author":"Kanis","year":"1997"},{"key":"10.4158\/EP161638.OR_bb0090","first-page":"243","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012"},{"key":"10.4158\/EP161638.OR_bb0095","first-page":"1130","article-title":"Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass","volume":"50","author":"Anastasilakis","year":"2012"},{"key":"10.4158\/EP161638.OR_bb0100","first-page":"226","article-title":"High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening","volume":"9","author":"Bettica","year":"1999"},{"key":"10.4158\/EP161638.OR_bb0105","first-page":"1026","article-title":"Longitudinal evaluation of vitamin D status in healthy subjects from southern Italy: seasonal and gender differences","volume":"12","author":"Carnevale","year":"2001"},{"key":"10.4158\/EP161638.OR_bb0110","first-page":"178","article-title":"Serum 25(OH)-vitamin D level in children: is there a need to change the reference range based on 2011 Institute of Medicine report?","volume":"52","author":"Srivastava","year":"2013"},{"key":"10.4158\/EP161638.OR_bb0115","first-page":"199","article-title":"Vitamin D and its emerging role in immunopathology","volume":"31","author":"Haroon","year":"2012"},{"key":"10.4158\/EP161638.OR_bb0120","first-page":"6144","article-title":"Transcriptional profiling of gamma delta T cells identifies a role for vitamin D in the immunoregulation of the V gamma 9V delta 2 response to phosphate-containing ligands","volume":"174","author":"Chen","year":"2005"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20392776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20392776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:32Z","timestamp":1761516272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20392776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1530891X20392776"],"URL":"https:\/\/doi.org\/10.4158\/ep161638.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP161638.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}